Effects of CDKN2B‐AS1 polymorphisms on the susceptibility to coronary heart disease

• Published in: Molecular genetics & genomic medicine Vol. 7; no. 11; pp. e955 - n/a
• Main Authors: Huang, Kang, Zhong, Jianghua, Li, Qiang, Zhang, Wei, Chen, Zibin, Zhou, Yilei, Wu, Miao, Zhong, Zanrui, Lu, Shijuan, Zhang, Shufang
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.11.2019; John Wiley and Sons Inc; Wiley
• Subjects: Age; Antisense RNA; Biomarkers; Blood platelets; Cardiovascular disease; Cardiovascular diseases; Case-Control Studies; case–control study; CDKN2B‐AS1; Cell cycle; Cell growth; Confidence intervals; Coronary artery disease; Coronary Disease - genetics; Coronary Disease - pathology; coronary heart disease; Deoxyribonucleic acid; Diabetes; Diabetes mellitus; DNA; Enzyme inhibitors; Family medical history; Female; Gender; Gene expression; Genetic Predisposition to Disease; Genetic testing; Genotype; Health risk assessment; Health risks; Heart; Heart diseases; Heterozygotes; Hospitals; Humans; Hypertension; Kinases; Male; Males; Middle Aged; Original; Polymorphism; Polymorphism, Single Nucleotide; Population; Prognosis; Regression analysis; Ribonucleic acid; Risk; Risk Factors; RNA; RNA, Long Noncoding - genetics; Software; Statistical analysis; Studies; Subgroups; subgroups analysis; Susceptibility; subgroups analysis; CDKN2B-AS1; coronary heart disease; polymorphism; case-control study
• ISSN: 2324-9269; 2324-9269
• DOI: 10.1002/mgg3.955

Background Coronary heart disease (CHD) is one of the most severe cardiovascular diseases. Cyclin‐dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B‐AS1) is a significant susceptibility locus for cardiovascular disease by regulating inflammation response and cell cycle. The aim of this study was to assess whether CDKN2B‐AS1 polymorphisms are associated with CHD risk in the Chinese Han population. Methods A total of 501 CHD patients and 496 healthy controls were recruited from Central South University Xiangya School of Medicine Affiliated Haikou Hospital, five CDKN2B‐AS1 polymorphisms (rs10115049, rs75227345, rs2383205, rs10738606, and rs1333049) were analyzed by the Agena MassARRAY platform. The association of CDKN2B‐AS1 polymorphisms and CHD risk was determined by odd ratios (OR) and 95% confidence intervals (CI) using logistic regression. Results CDKN2B‐AS1 rs10738606 was significantly associated with CHD under codominant (p = .03), dominant (p = .019), recessive (p = .010), additive (p = .003), and allele (p = .003) models. Gender‐based subgroup tests showed that four polymorphisms (rs75227345, rs2383205, rs10738606 and rs1333049) were associated with CHD in males (p < .05). And age‐based subgroup tests indicated that rs2383205 and rs10738606 were associated with CHD among individuals, respectively (p < .05). For CHD patients, rs1333049 decreased the risk of diabetes under heterozygote (p = .014) and dominant (p = .024) models. Conclusions In conclusion, CDKN2B‐AS1 polymorphisms were associated with CHD risk in the combined or subgroup tests, suggesting an important role of CDKN2B‐AS1 in CHD susceptibility. CDKN2B‐AS1 polymorphisms were associated with coronary heart disease (CHD) in the combined or subgroup tests, suggesting an important role of CDKN2B‐AS1 in CHD susceptibility.